Everyone in biotech talks about capital efficiency these days. Doing more with less financing, more disciplined tranching of rounds, leaner organizations, lower expenses, etc.  But paradoxically, as a sector, there’s universal praise and admiration for those individuals and companies who

As my first post of real content, I thought I’d tackle the question of what are the actual return distributions of venture capital investments in biotech startups (e.g., how many losers, how many winners) to set some context.  And it

I’ve decided it’s time to experiment with blogging about the biotech venture ecosystem.  I’d like to call it a “pilot study”.  If it ends up being safe and effective over the next few months, I’ll continue.  If not, I’ll terminate